Icade Shares Decline at Close Despite Target Revision
Icade shares ended the session on Wednesday, January 28, 2026, at 20.98 euros, showing a limited increase of 0.96% compared to the previous close. This performance comes as several banking institutions have recently revised their strategy on the real estate investment trust, amid an ongoing pressured real estate market.
The week was marked by two significant analyst revisions on the stock. On January 26, UBS made a radical shift by lowering its price target from 37 euros to 19 euros and initiating a sell recommendation on the real estate investment trust. This new target implies a downside potential of 9.5% from the current stock level. Conversely, on January 23, Goldman Sachs raised its target from 14.60 euros to 17.40 euros, while maintaining its negative recommendation. Despite this upward adjustment, the target of the American bank remains 17% below the closing prices observed this Wednesday. These divergences illustrate the difficulties of the listed real estate sector in regaining visibility in an unfavorable interest rate environment.
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
Technical analysis reveals a deteriorated situation for the group. The 14-day RSI stands at 22, clearly placing the stock in an oversold zone, a level that generally indicates excessive selling pressure in the short term. This configuration could suggest a weakening of the bearish movement, although it does not predict an imminent turnaround. Furthermore, the stock price is below its 20-day moving average, positioned at 21.37 euros, representing a gap of 1.8%. Over a longer horizon, performances remain negative with a decline of 1.78% over three months and 5.67% over a year. The monthly volatility stands at 8.35, indicating persistent nervousness in the listed real estate sector, which is still in search of a positive catalyst.
Confirmation de la guidance annuelle 2026 avec un CFNC Groupe attendu entre 2,90 € et 3,10 € par action
Risks mentioned
Baisse de valeur du patrimoine de -3,1 % à périmètre constant, dont -2,8 % sur les bureaux
Réversion négative attendue sur les renouvellements de baux, potentiel de -7,1 % sur les loyers faciaux
Coût moyen de la dette en hausse à 1,85 %, attendu à environ 2 % fin 2026 ; ICR dégradé à 3,8x
Opportunities identified
Promesse de vente des actifs de santé au Portugal, environ 75 M€ en quote-part Icade
Acquisition des 49 % de la Tour Eqho avec un rendement supérieur à 8 %, relutive sur le CFNC
Réservations résidentielles en hausse de 11,9 % en volume et 6,4 % en valeur
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
